www.onclive.com
Iza-Bren Significantly Improves PFS vs Chemotherapy in Pretreated HR+/HER2– Advanced Breast Cancer | OncLive
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
Bluesky · Hashtag
#bcsm
44
posts · 30d
13
users
1
posts / day
3.4
posts / user
-77% vs last week
#bcsm is an active hashtag on Bluesky. In the last 30 days, 13 people shared 44 posts with it — around 1 a day. Activity is down 77% versus the previous week, peaking on Oct 8 with 6 posts.
#bcsm posts per day (last 30 days)
Related tags
Tags most often used together with #bcsm.
Posts with #bcsm
Dato-DXd improved CNS PFS and IC response vs investigator's choice of chemotherapy in locally recurrent inoperable or metastatic TNBC and baseline brain metastases for whom IO was not an option #ESMO26 #bcsm #oncology
Dive into the TROPION-Breast02 subgroup data: www.onclive.com/view/firs….
0 0 0
📈 Neoadjuvant T-DXd followed by THP elicited faster and deeper tumor responses on MRI than ddAC-THP in HER2+ early breast cancer, but MRI response did not reliably predict pCR in a DESTINY-Breast11 analysis. @myesmo.bsky.social #ESMO2026 #bcsm #oncology
Read more: www.onclive.com/view/t-dx….
0 0 0
📈 Significant PFS improvements were shown with iza-bren vs chemotherapy in pretreated HR+/HER2– advanced breast cancer, according to new data from the phase 3 PANKU-Breast01 trial
Read more here ➡️: www.onclive.com/view/pank….
#bcsm #oncology #ESMO26 @myesmo.bsky.social
0 0 0
Adjuvant giredestrant sustained physical functioning, role functioning, and HRQOL and was associated with sustained low AE bother vs SOC in ER+, HER2– early breast cancer, according to PROs from lidERA Breast Cancer. @myesmo.bsky.social #ESMO2026 #bcsm #oncology
www.onclive.com/view/adju….
0 0 0
The FDA has granted 510(k) clearance to TumorSight Risk, an AI-based software that estimates 5- and 10-year RFS from routine breast MRI, pathology, and clinical data for patients with HR+ HER2–, stage I to IIIA breast cancer. #bcsm #oncology
www.onclive.com/view/fda-….
www.onclive.com
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer | OncLive
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
1 0 0
🎥 Megan Kruse, MD, of @clevelandclinic.bsky.social, discusses the potential utility of FES-PET/CT in lobular breast cancer for Global Lobular Breast Cancer Awareness Day. #BreastCancerAwarenessMonth #bcsm #oncology
Read on for more lobular disease insights ➡️: www.onclive.com/view/refi….
0 0 2
In this episode of #OncologyUnplugged, Chandler Park, MD, and Jame Abraham, MD, discuss breast cancer management & the role of AI. @clevelandclinic.bsky.social #bcsm #oncology
Watch on our site or listen on your favorite podcast platforms!
www.onclive.com/view/biol….
0 0 1
Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911
Read the article. bit.ly/3VGspka
#BreastCancer #bcsm
0 2 3
❓FAQ ❓: Sara Nunnery, MD, and Annie Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment. #BreastCancerBriefing #bcsm #oncology
Read more ➡️: www.onclive.com/view/freq….
www.onclive.com
Frequently Asked Questions on Breast Cancer Patient Support, Self-Advocacy, and Survivorship | OncLive
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
0 0 0
Q4: What are the next steps for #AYACancer innovation? #AYACSM
#GYNCSM #ONCOLOGY #CANCERRESEARCH #TYACANCER #BTSM #BCSM #LCSM
1 1 2
Revisit the 2025 American Cancer Society report providing statistics on lobular breast cancer in the United States: bit.ly/4j6HFAI
The article is also featured in Wiley's #BreastCancerAwareness collection: bit.ly/3VNLroL
@americancancersoc.bsky.social
#BCAM #BCSM 🩷
0 0 0
Dato-DXd improved CNS PFS and IC response vs investigator's choice of chemotherapy in locally recurrent inoperable or metastatic TNBC and baseline brain metastases for whom IO was not an option #ESMO26 #bcsm #oncology
Dive into the TROPION-Breast02 subgroup data: www.onclive.com/view/firs….
0 0 0
📈 Neoadjuvant T-DXd followed by THP elicited faster and deeper tumor responses on MRI than ddAC-THP in HER2+ early breast cancer, but MRI response did not reliably predict pCR in a DESTINY-Breast11 analysis. @myesmo.bsky.social #ESMO2026 #bcsm #oncology
Read more: www.onclive.com/view/t-dx….
0 0 0
📈 Significant PFS improvements were shown with iza-bren vs chemotherapy in pretreated HR+/HER2– advanced breast cancer, according to new data from the phase 3 PANKU-Breast01 trial
Read more here ➡️: www.onclive.com/view/pank….
#bcsm #oncology #ESMO26 @myesmo.bsky.social
www.onclive.com
Iza-Bren Significantly Improves PFS vs Chemotherapy in Pretreated HR+/HER2– Advanced Breast Cancer | OncLive
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
0 0 0
Adjuvant giredestrant sustained physical functioning, role functioning, and HRQOL and was associated with sustained low AE bother vs SOC in ER+, HER2– early breast cancer, according to PROs from lidERA Breast Cancer. @myesmo.bsky.social #ESMO2026 #bcsm #oncology
www.onclive.com/view/adju….
0 0 0
The FDA has granted 510(k) clearance to TumorSight Risk, an AI-based software that estimates 5- and 10-year RFS from routine breast MRI, pathology, and clinical data for patients with HR+ HER2–, stage I to IIIA breast cancer. #bcsm #oncology
www.onclive.com/view/fda-….
www.onclive.com
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer | OncLive
The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.
1 0 0
❓FAQ ❓: Sara Nunnery, MD, and Annie Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment. #BreastCancerBriefing #bcsm #oncology
Read more ➡️: www.onclive.com/view/freq….
www.onclive.com
Frequently Asked Questions on Breast Cancer Patient Support, Self-Advocacy, and Survivorship | OncLive
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
0 0 0
🎥 Megan Kruse, MD, of @clevelandclinic.bsky.social, discusses the potential utility of FES-PET/CT in lobular breast cancer for Global Lobular Breast Cancer Awareness Day. #BreastCancerAwarenessMonth #bcsm #oncology
Read on for more lobular disease insights ➡️: www.onclive.com/view/refi….
0 0 2
In this episode of #OncologyUnplugged, Chandler Park, MD, and Jame Abraham, MD, discuss breast cancer management & the role of AI. @clevelandclinic.bsky.social #bcsm #oncology
Watch on our site or listen on your favorite podcast platforms!
www.onclive.com/view/biol….
0 0 1
Revisit the 2025 American Cancer Society report providing statistics on lobular breast cancer in the United States: bit.ly/4j6HFAI
The article is also featured in Wiley's #BreastCancerAwareness collection: bit.ly/3VNLroL
@americancancersoc.bsky.social
#BCAM #BCSM 🩷
0 0 0
Now out in #JCO!
NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. Co-authored by @Docace911
Read the article. bit.ly/3VGspka
#BreastCancer #bcsm
0 2 3
🌟 Matthew P. Goetz, MD, of @mayocliniccancer.bsky.social, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer. #BreastCancerAwarenessMonth #bcsm #oncology
Read more ➡️: www.onclive.com/view/pati….
www.onclive.com
Patient Factors Help Individualize Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Use in HR+ Breast Cancer | OncLive
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
0 0 0
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.